Business Context and Reporting Period
This is TradeUP Acquisition Corp.’s unaudited Form 10-Q for the three months ended March 31, 2023, not a report from an already-combined Estrella Immunopharma. TradeUP was a shell company seeking to merge with preclinical-stage Estrella Biopharma, Inc.; the proposed transaction would rename the combined company Estrella Immunopharma, Inc. The filing describes expected merger consideration of $325 million, or 32.5 million shares at $10 per share. The transaction had not closed as of the reporting period.
TradeUP reported no operating revenue. Its income was non-operating dividend income from investments in its trust account.
Financial Results and Position
- Q1 2023: Net loss was $63,325, versus a $141,252 net loss in Q1 2022. Formation and operating costs were $136,550, franchise taxes $13,100, and income tax provision $19,465; trust-account dividend income of $105,790 partly offset these costs. The comparable 2022 dividend income was $3,688.
- Revenue and margins: No operating revenue was reported; operating margins are not meaningful for this shell company.
- Cash flow: Operating activities used $275,718, compared with $157,144 in Q1 2022. Investing activities provided $77,773 and financing activities provided $186,533. Cash declined $11,412 to $29,390.
- Assets and liquidity: Total assets were $9.78 million, including $9.70 million in the restricted trust account. Cash outside the trust was $29,390; working capital deficit was $1,133,684. Management said the deficit and the business-combination deadline raise substantial doubt about the company’s ability to continue as a going concern.
- Liabilities and equity: Total liabilities were $2.77 million, including $1.22 million of current liabilities and $1.55 million in deferred underwriters’ marketing fees payable only if a business combination closes. The balance sheet also reported $9.54 million of redeemable shares as temporary equity and a $2.53 million stockholders’ deficit.
- Borrowings: At March 31, promissory notes were $136,533 and related-party working capital loans were $598,600. Separately, Estrella’s extension payments were evidenced by notes; the filing reports $182,044 of payments for four monthly extensions, while the March 31 balance-sheet note amount is $136,533.
Changes, Outlook, Risks, and Unusual Items
- The net loss narrowed year over year, mainly as trust-account dividend income rose to $105,790 from $3,688; operating costs increased to $136,550 from $120,740.
- At the December 2022 extension vote, 3,519,780 public shares were redeemed, leaving 910,220 redeemable public shares. Their reported redemption value rose to $10.48 per share from $10.25 at year-end.
- Estrella funded monthly trust-account extensions. The filing says the current business-combination deadline was May 19, 2023, with extensions permitted up to July 19, 2023. Failure to complete a combination by the applicable deadline would require liquidation; warrants would expire worthless.
- After quarter-end, TradeUP disclosed Nasdaq deficiencies concerning market value of listed securities and minimum public holders. The notices were not immediate delisting decisions; the filing described compliance periods and said there was no assurance of regaining compliance.
- After quarter-end, TradeUP also disclosed a White Lion agreement giving it the option, after the combination, to sell up to $50 million of newly issued common stock, subject to conditions. An amendment provided for Estrella to issue White Lion 250,000 shares of Estrella Series A preferred stock immediately before the proposed closing.
- Management reported ineffective disclosure controls due to a material weakness in accounting for complex equity instruments, following a restatement related to redeemable-share classification. Management described planned training and increased review, but gave no assurance those measures would be sufficient.
- The filing identifies potential risks from limited cash outside the trust, reliance on related-party financing, transaction completion and redemption levels, Nasdaq compliance, and a possible 1% federal excise tax on certain stock repurchases or redemptions.
- No financial guidance or quantified operating outlook was provided. Management said it expected continued public-company and transaction costs and that it would not generate operating revenue before a business combination.
Most Important Facts to Verify
- Confirm the filing entity and status: the document is filed by TradeUP Acquisition Corp., while the requested company name is Estrella Immunopharma, Inc.; the name change was conditional on closing the merger.
- Verify the merger’s closing status, consideration, remaining approval conditions, and the applicable extension deadline. The filing reports May 19, 2023 as the current deadline and July 19, 2023 as the maximum date.
- Reconcile the extension-note amounts and timing: $136,533 appears as the March 31 promissory-note balance, while $182,044 is stated for four extension payments.
- Assess available cash and funding needs against the $1.13 million working capital deficit, $598,600 related-party loans, and management’s going-concern warning.
- Check subsequent Nasdaq compliance updates and the potential dilution and terms associated with the White Lion financing arrangement.
- Review remediation of the disclosed material weakness and note filing-text inconsistencies, including the signature date shown as May 17, 2022 despite the report’s 2023 period and other references to May 2023.